Peripheral blood stem cell transplantation from HLA-mismatched unrelated donor or haploidentical donor for the treatment of X-linked agammaglobulinemia
NIE Ling, SU Tao, YANG Kai-Tai, ZHAO Liang, HU Jian, YANG Shuang-Hui, XU Ya-Jing, FU Bin
Department of Hematology, Xiangya Hospital, Central South University, Changsha 410008, China
Abstract：Allogeneic stem cell transplantation (allo-SCT) is currently the only curative option for patients with X-linked agammaglobulinemia (XLA). In this study, patient 1 aged 4 years who underwent allogeneic peripheral blood stem cell transplantation (allo-PBSCT) from HLA-mismatched unrelated donor; patient 2 aged 24 years (childhood onset) with primary cutaneous acral CD8+ T cell lymphoma who underwent allo-PBSCT from haploidentical relative donor. Both were treated by reduced toxicity myeloablative conditioning with post-transplantation cyclophosphamide (PTCy), anti-thymocyte globulin (ATG), methotrexate (MTX) and cyclosporine (CsA) for graft-versus-host-disease (GVHD) prophylaxis. In patient 1, neutrophil and platelet engraftment were observed on day 11 post-transplantation; the donor chimerism dropped on day 90 post-transplantation, and recovered on day 150 with donor lymphocyte infusion (DLI). In patient 2, neutrophil and platelet engraftment were observed on days 20 and 87 post-transplantation respectively, with complete donor chimerism on day 30 post-transplantation. The serum levels of IgG, IgM and IgA and the percentage of CD19+ B cells in peripheral blood of patients 1 and 2 returned to normal within 2 months and more than 1 year after transplantation respectively. There was no evidence of acute GVHD for the two patients. Patient 1 developed a limited type of skin chronic GVHD after DLI, which disappeared after anti-GVHD treatment. This is the first report of successful treatment for two XLA patients using PTCy with allo-PBSCT from HLA-mismatched unrelated donor or haploidentical donor, combining with improved conditioning, which expands the pool of eligible donors for patients with XLA.
NIE Ling,SU Tao,YANG Kai-Tai et al. Peripheral blood stem cell transplantation from HLA-mismatched unrelated donor or haploidentical donor for the treatment of X-linked agammaglobulinemia[J]. CJCP, 2020, 22(8): 821-827.
Staines Boone AT, Torres Martínez MG, López Herrera G, et al. Gastric adenocarcinoma in the context of X-linked agammaglobulinemia:case report and review of the literature[J]. J Clin Immunol, 2014, 34(2):134-137.
[2]
Shillitoe B, Gennery A. X-linked agammaglobulinaemia:outcomes in the modern era[J]. Clin Immunol, 2017, 183(10):54-62.
Abu-Arja RF, Chernin LR, Abusin G, et al. Successful hematopoietic cell transplantation in a patient with X-linked agammaglobulinemia and acute myeloid leukemia[J]. Pediatr Blood Cancer, 2015, 62(9):1674-1676.
[7]
Ikegame K, Imai K, Yamashita M, et al. Allogeneic stem cell transplantation for X-linked agammaglobulinemia using reduced intensity conditioning as a model of the reconstitution of humoral immunity[J]. J Hematol Oncol, 2016, 9:9.
[8]
Vellaichamy Swaminathan V, Uppuluri R, Patel S, et al. Treosulfan-based reduced toxicity hematopoietic stem cell transplantation in X-linked agammaglobulinemia:a cost-effective alternative to long-term immunoglobulin replacement in developing countries[J]. Pediatr Transplant, 2020, 24(1):e13625.
[9]
van Zelm MC, Pumar M, Shuttleworth P, et al. Functional antibody responses following allogeneic stem cell transplantation for TP53 mutant pre-B-ALL in a patient with X-linked agammaglobulinemia[J]. Front Immunol, 2019, 10:895.
[10]
Xu L, Fu B, Wang W, et al. Haploidentical hematopoietic cell transplantation for severe acquired aplastic anemia:a case-control study of post-transplant cyclophosphamide included regimen vs. anti-thymocyte globulin & colony-stimulating factor-based regimen[J]. Sci China Life Sci, 2020, 63(6):940-942.
[11]
Anurathapan U, Hongeng S, Pakakasama S, et al. Hematopoietic stem cell transplantation for severe thalassemia patients from haploidentical donors using a novel conditioning regimen[J]. Biol Blood Marrow Transplant, 2020, 26(6):1106-1112.
[12]
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants:a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5):405-424.
[13]
Väliaho J, Faisal I, Ortutay C, et al. Characterization of all possible single-nucleotide change caused amino acid substitutions in the kinase domain of Bruton tyrosine kinase[J]. Hum Mutat, 2015, 36(6):638-647.
[14]
Lougaris V, Soresina A, Baronio M, et al. Long-term follow-up of 168 patients with X-linked agammaglobulinemia reveals increased morbidity and mortality[J]. J Allergy Clin Immunol, 2020. DOI:10.1016/j.jaci.2020.03.001. Online ahead of print.
[15]
Winkelstein JA, Marino MC, Lederman HM, et al. X-linked agammaglobulinemia:report on a United States registry of 201 patients[J]. Medicine (Baltimore), 2006, 85(4):193-202.
[16]
Howard V, Greene JM, Pahwa S, et al. The health status and quality of life of adults with X-linked agammaglobulinemia[J]. Clin Immunol, 2006, 118(2-3):201-208.
[17]
Hurst JR, Workman S, Garcha DS, et al. Activity, severity and impact of respiratory disease in primary antibody deficiency syndromes[J]. J Clin Immunol, 2014, 34(1):68-75.
[18]
Gennery AR, Slatter MA, Grandin L, et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe:entering a new century, do we do better?[J]. J Allergy Clin Immunol, 2010, 126(3):602-610.e1-e11.
[19]
Kasamon YL, Bolaños-Meade J, Prince GT, et al. Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults[J]. J Clin Oncol, 2015, 33(28):3152-3161.
[20]
Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation:HLA-C mismatching is associated with a strong adverse effect on transplantation outcome[J]. Blood, 2004, 104(7):1923-1930.
[21]
Bradstock KF, Bilmon I, Kwan J, et al. Single-agent high-dose cyclophosphamide for graft-versus-host disease prophylaxis in human leukocyte antigen-matched reduced-intensity peripheral blood stem cell transplantation results in an unacceptably high rate of severe acute graft-versus-host disease[J]. Biol Blood Marrow Transplant, 2015, 21(5):941-944.
[22]
Bashey A, Zhang MJ, Mccurdy SR, et al. Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell-replete haploidentical donor transplantation using post-transplant cyclophosphamide[J]. J Clin Oncol, 2017, 35(26):3002-3009.
[23]
Robinson TM, O'donnell PV, Fuchs EJ, et al. Haploidentical bone marrow and stem cell transplantation:experience with post-transplantation cyclophosphamide[J]. Semin Hematol, 2016, 53(2):90-97.
[24]
Salas MQ, Prem S, Atenafu EG, et al. Reduced intensity allogeneic stem cell transplant with anti-thymocyte globulin and post-transplant cyclophosphamide in acute myeloid leukemia[J]. Eur J Haematol, 2019, 103(5):510-518.
[25]
Medina D, Estacio M, Rosales M, et al. Haploidentical stem cell transplant with post-transplantation cyclophosphamide and mini-dose methotrexate in children[J]. Hematol Oncol Stem Cell Ther, 2020. DOI:10.1016/j.hemonc.2020.01.003. Online ahead of print.
